Bon Health Review

Our assessment

Bon Health has the best-built pricing table in this comparison. Four commitment tiers, each showing the per-month rate, the up-front total and the saving on the same rung, so you can't pick the cheap number without seeing what it costs to buy. Everything else asks for more caution. The figure the page opens with is the quarterly rate, sitting beside a struck-through monthly one with no term named. The first-order discount is advertised as a percentage rather than a price. And the Mounjaro page carries a complete four-rung brand ladder for a product the same page badges Coming Soon.

The pricing grid shows what you actually hand over

Most sellers here publish a from figure and let you find out later what it assumed. Bon Health publishes a grid: monthly, quarterly, six months, annual. Each row gives the billing frequency in words, the effective per-month rate in brackets, the total actually charged, and the saving against paying monthly, as both a dollar amount and a percentage.

That last column is what makes it unusual. Told that the annual tier saves nearly half, you can see immediately what you would hand over on day one, and decide whether you want to be locked in that long with a compounded product. Cora Health publishes every tier too; Bon is the one that puts the total and the discount on the same line as the rate.

The FAQ on each page closes the loop, restating the cheapest tier and the month-to-month tier in the same sentence. Both ends of the ladder are on the page.

The number you land on isn't the month-to-month rate

The top of each product page shows a per-month figure beside a struck-through, higher one, in the visual grammar every shopper reads as a sale. It is not a sale. The lower figure is the quarterly tier and the struck-out one is the month-to-month rate, and the hero says none of that. It prints the two numbers and the words Original price.

The explanation exists, but it sits behind the page's own tab strip, under Pricing rather than the Description you arrive on. So the term attached to the headline number takes a click to find, on a page that has otherwise gone to real trouble to be clear.

The first-order promotion has the same shape. It is stated as a percentage off, with free nausea medication thrown in, and never as a figure. So the amount you actually pay in month one is not published anywhere on the page.

A brand-name price ladder for a drug you can't buy

There is a Mounjaro product page, built like every other product page, with a hero figure, a struck-through figure, and a four-rung ladder running from a monthly charge to a yearly total in five figures. It looks like an offer right up to the button, which doesn't say Get started. It says Coming Soon, above the line Available soon — see our compounded version in the meantime.

None of those rungs is a price you can pay, so Bon Health is not a route to Mounjaro today, and its own page says so. Zera Health does something adjacent and worse — four brand pages whose footer says the company does not supply the drugs — so expect to meet this pattern again.

What the page is honest about is where it steers you. The Mounjaro copy states plainly that the brand's price is set by Eli Lilly, and that it commonly runs well over a thousand dollars a month without insurance. It then says the compounded tirzepatide is the cheaper route through Bon. That is a fair comparison, printed by the seller, on a page selling the more expensive thing.

The sentence that cost another seller here a warning letter

Both compounded product pages describe the drug as having the same active ingredient as the brand: Ozempic and Wegovy on the semaglutide page, Mounjaro and Zepbound on the tirzepatide page. The homepage repeats it.

In September 2025 the FDA sent a warning letter to Lovely Meds, also reviewed here, quoting that exact construction: same active ingredient as Wegovy and Ozempic, same active ingredient as Zepbound and Mounjaro. The letter said those claims imply a compounded product is the same as an FDA-approved one when it is not, which misbrands it. The FDA's public warning-letter database carries no letter to Bon Health Corporation. Nothing here says Bon Health has done anything wrong; only that the agency has objected to this wording elsewhere in this comparison, and you are better off knowing that than not.

In Bon Health's favor, the disclaimer sits in three separate places on the same pages: beneath the results chart, in the eligibility paragraph, and in the footer. Each one says in plain words that compounded drugs are not FDA-approved and that the FDA does not evaluate them for safety, effectiveness or quality. Several sellers here bury that line or drop it. This one repeats it next to the brand it is comparing itself against.

What it won't tell you

No pharmacy is named. The homepage strip says 503A and 503B compounding, which is a regulatory class rather than a company. Both the privacy policy and the Terms say only that medications are dispensed by independently owned and operated U.S.-licensed pharmacies. Ondra Health names six and gives the class of each; Cora Health names two.

No clinician is named either. The Terms describe individual licensed clinicians employed by or contracted with medical groups, and never name a group or a person. So the two questions most buyers want answered before paying — who prepares this, and who is prescribing it — both come back as categories.

The state answer is better. The homepage says licensed in all 50 states and repeats it in a second stat line about physicians in every one, with no exclusion anywhere on the site. That is a real answer, and more than most of this field gives.

The legal entity is Bon Health Corporation, a Delaware corporation, named in the first sentence of both the privacy policy and the Terms. One oddity if you go looking: the cookies URL on this site doesn't serve a cookies page. It redirects to the privacy policy.